Veozah (fezolinetant) — Highmark
moderate to severe vasomotor symptoms due to menopause
Preferred products
- generic hormone therapy product
Initial criteria
- age ≥ 18 years
- used for moderate to severe vasomotor symptoms due to menopause (ICD-10: N95.1)
- member has experienced therapeutic failure, contraindication, or intolerance to a generic hormone therapy product OR prescriber attests that hormone therapy is not clinically appropriate
Reauthorization criteria
- prescriber attests member has experienced positive clinical response to therapy
Approval duration
12 months